Spinal muscular atrophy-like phenotype in a mouse model of acid ceramidase deficiency

Commun Biol. 2023 May 25;6(1):560. doi: 10.1038/s42003-023-04932-w.

Abstract

Mutations in ASAH1 have been linked to two allegedly distinct disorders: Farber disease (FD) and spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). We have previously reported FD-like phenotypes in mice harboring a single amino acid substitution in acid ceramidase (ACDase), P361R, known to be pathogenic in humans (P361R-Farber). Here we describe a mouse model with an SMA-PME-like phenotype (P361R-SMA). P361R-SMA mice live 2-3-times longer than P361R-Farber mice and have different phenotypes including progressive ataxia and bladder dysfunction, which suggests neurological dysfunction. We found profound demyelination, loss of axons, and altered sphingolipid levels in P361R-SMA spinal cords; severe pathology was restricted to the white matter. Our model can serve as a tool to study the pathological effects of ACDase deficiency on the central nervous system and to evaluate potential therapies for SMA-PME.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Distal Myopathies
  • Farber Lipogranulomatosis* / genetics
  • Farber Lipogranulomatosis* / metabolism
  • Farber Lipogranulomatosis* / pathology
  • Humans
  • Mice
  • Muscular Atrophy, Spinal* / genetics
  • Muscular Atrophy, Spinal* / pathology
  • Myoclonic Epilepsies, Progressive* / genetics
  • Myoclonic Epilepsies, Progressive* / pathology
  • Myoclonus / congenital
  • Phenotype
  • Sphingolipids / metabolism

Substances

  • Sphingolipids

Supplementary concepts

  • Jankovic Rivera syndrome

Grants and funding